Division of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan.
Division of Nephrology, Tokyo Teishin Hospital, Tokyo, Japan.
Kidney Int. 2017 Jul;92(1):154-164. doi: 10.1016/j.kint.2017.01.014. Epub 2017 Mar 17.
Vascular adhesion protein-1 (VAP-1) is a unique molecule since it acts as an adhesion molecule as well as an ectoenzyme catalyzing oxidative deamination of primary amines and generates hydrogen peroxide in the extracellular space. While VAP-1 is implicated in various inflammatory diseases, its role in acute kidney injury is less characterized. Here we studied VAP-1 expression in the kidney and the effect of its inhibition in a rat model of renal ischemia/reperfusion injury. VAP-1 was predominantly expressed in pericytes, which released enzymatically active enzyme. In vivo, a specific VAP-1 inhibitor, RTU-1096, significantly ameliorated rat renal ischemia/reperfusion injury and decreased neutrophil infiltration measured 12 hours after injury without altering macrophage or T lymphocyte populations. The protective effect of VAP-1 inhibition was lost in neutrophil-depleted rats, suggesting its inhibition ameliorated renal ischemia/reperfusion injury by suppressing neutrophil infiltration. To investigate whether hydrogen peroxide generated by VAP-1 enzyme reaction enhances neutrophil infiltration, we conducted an under-agarose migration assay with purified human neutrophils. Recombinant human VAP-1 significantly induced neutrophil migration, which was almost completely inhibited by RTU-1096 or catalase. Thus, VAP-1 plays a critical role in the pathophysiology of renal ischemia/reperfusion injury by enhancement of neutrophil infiltration generating a local hydrogen peroxide gradient. Hence, VAP-1 inhibition may be a novel therapy in ischemic acute kidney injury.
血管黏附蛋白-1(VAP-1)是一种独特的分子,因为它既是一种黏附分子,又是一种细胞外酶,可催化伯胺的氧化脱氨,并在细胞外空间生成过氧化氢。虽然 VAP-1 与多种炎症性疾病有关,但它在急性肾损伤中的作用尚未得到充分描述。在这里,我们研究了 VAP-1 在肾脏中的表达及其在大鼠肾缺血/再灌注损伤模型中的抑制作用。VAP-1 主要在周细胞中表达,周细胞释放具有酶活性的酶。在体内,一种特异性 VAP-1 抑制剂 RTU-1096 显著改善了大鼠肾缺血/再灌注损伤,并在损伤后 12 小时减少了中性粒细胞浸润,而不改变巨噬细胞或 T 淋巴细胞群体。在中性粒细胞耗竭大鼠中,VAP-1 抑制的保护作用丧失,表明其抑制作用通过抑制中性粒细胞浸润改善了肾缺血/再灌注损伤。为了研究 VAP-1 酶反应产生的过氧化氢是否增强中性粒细胞浸润,我们用纯化的人中性粒细胞进行了琼脂下迁移实验。重组人 VAP-1 显著诱导中性粒细胞迁移,而 RTU-1096 或过氧化氢酶几乎完全抑制了迁移。因此,VAP-1 通过增强产生局部过氧化氢梯度的中性粒细胞浸润,在肾缺血/再灌注损伤的病理生理学中发挥关键作用。因此,VAP-1 抑制可能是缺血性急性肾损伤的一种新疗法。